

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT CORNEAL CONFOCAL MICROSCOPY OBTAINED NATIONAL MEDICAL DEVICE REGISTRATION CERTIFICATE

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, the corneal confocal microscopes T3–600 and T3–400 independently developed by Gaush Neotech Ltd* (高視創新科技有限公司) (“**Gaush Neotech**”), a wholly-owned subsidiary of the Company, recently obtained the medical device registration certificate approved by Jiangsu Medical Products Administration.

Such corneal confocal microscopy has achieved an industry breakthrough through technological innovation, becoming the first device of its kind in China that features both a wide field of view and high resolution. Such device uses a laser light source and tomographic confocal scanning technology to increase the scanning field of view to 600×600μm, with an optical resolution of 1.1μm and a digital resolution of 0.4μm, significantly improving the imaging quality. Corneal confocal microscopy can observe the cornea and conjunctiva in vivo, and assist in the diagnosis of various corneal and conjunctival diseases (such as infectious diseases, non-infectious diseases including corneal degeneration, malnutrition, immune lesions and keratoconus, as well as surgery-related, traumatic, dry eye, and systemic disease-related corneal lesions, etc.), providing a basis for disease diagnosis and condition assessment.

Gaush Neotech has planned an AI function expansion path for T3 products. In the future, AI technology will be used to realize functions such as automatic image analysis to improve diagnostic efficiency and accuracy. At the same time, the CE registration process for T3 products has been started simultaneously.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, April 9, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purpose only*